Downregulation of GLT1D1 significantly decreases PD- L1 glycosylation, which leads to a significantly higher proportion of non-glycosylated PD-L1, enhances cytotoxic activity of cytotoxic T cells against lymphoma cells, and influences PD- L1/PD-1 interaction, implying that GLT1D1 can be a novel target for immunosuppressive therapy in non-Hodgkin’s lymphoma (29). Here, GLT1D1 is linked to non-Hodgkin lymphoma.